Archive

2011, Vol. 121, No. 3

March 01, 2011

Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease

Małgorzata Saryusz‑Wolska, Elektra Szymańska‑Garbacz, Maciej Jabłkowski, Jolanta Białkowska, Maciej Pawłowski, Ewa Kwiecińska, Aleksandra Omulecka, Anna Borkowska, Anna Ignaczak, Jerzy Loba, Leszek Czupryniak

Pol Arch Intern Med. 2011, Vol. 121, No. 3: 61-66 / DOI: 10.20452/pamw.1023

Assessment of skin autofluorescence as a marker of advanced glycation end product accumulation in type 1 diabetes

Paweł Samborski, Dariusz Naskręt, Aleksandra Araszkiewicz, Paweł Niedźwiecki, Dorota Zozulińska‑Ziółkiewicz, Bogna Wierusz‑Wysocka

Pol Arch Intern Med. 2011, Vol. 121, No. 3: 67-72 / DOI: 10.20452/pamw.1025

Dabigatran as anticoagulant therapy for atrial fibrillation. Which patients should receive it, which patients may not need it, and other practical aspects of patient management

James D. Douketis

Pol Arch Intern Med. 2011, Vol. 121, No. 3: 73-80 / DOI: 10.20452/pamw.1027

Do we have enough data to confirm the link between antidiabetic drug use and cancer development?

Józef Drzewoski, Agata Drozdowska, Agnieszka Śliwińska

Pol Arch Intern Med. 2011, Vol. 121, No. 3: 81-87 / DOI: 10.20452/pamw.1029

Can we prolong life of patients with advanced chronic kidney disease: what is the clinical evidence?

Tomasz Stompór, Artur Olszewski, Irena Kierzkowska

Pol Arch Intern Med. 2011, Vol. 121, No. 3: 88-93 / DOI: 10.20452/pamw.1031

Impact Factor 2022

4.8

IC value for 2022

217.18

Ministry of Education and Science score

200

Average times from:
submission to 1st decision, 2 days
submission to first reviews, 24 days
acceptance to online first publication, 5 days
acceptance to final publication, 45 days

Current manuscript acceptance rate: 27%

The journal is co-financed from the state budget under the "Development of scientific journals" program of the Ministry of Education and Science in the years 2022-2024. Read more